The introduction of new vaccines into developing countries. IV: Global Access Strategies
- PMID: 17363119
- DOI: 10.1016/j.vaccine.2007.02.047
The introduction of new vaccines into developing countries. IV: Global Access Strategies
Abstract
This paper offers a framework for managing a comprehensive Global Access Strategy for new vaccines in developing countries. It is aimed at strengthening the ability of public-sector entities to reach their goals. The Bill and Melinda Gates Foundation and The Rockefeller Foundation have been leaders in stimulating the creation of new organizations - public/private product development partnerships (PDPs) - that seek to accelerate vaccine development and distribution to meet the health needs of the world's poor. Case studies of two of these PDPs - the Salmonella Anti-pneumococcal Vaccine Program and the Pediatric Dengue Vaccine Initiative - examine development of such strategies. Relying on the application of innovation theory, the strategy leads to the identification of six Components of Innovation which cover all aspects of the vaccine innovation process. Appropriately modified, the proposed framework can be applied to the development and introduction of other products in developing countries including drugs, and nutritional and agricultural products.
Similar articles
-
Public-private partnerships for health: their main targets, their diversity, and their future directions.Bull World Health Organ. 2001;79(8):713-20. Epub 2001 Oct 24. Bull World Health Organ. 2001. PMID: 11545327 Free PMC article.
-
GAVI and the Vaccine Fund--a boon for immunization in the developing world.Indian J Public Health. 2004 Apr-Jun;48(2):45-8. Indian J Public Health. 2004. PMID: 15709583
-
PneumoADIP: an example of translational research to accelerate pneumococcal vaccination in developing countries.J Health Popul Nutr. 2004 Sep;22(3):268-74. J Health Popul Nutr. 2004. PMID: 15609779
-
Public-private partnerships: an overview.Trans R Soc Trop Med Hyg. 2005 Oct;99 Suppl 1:S1-8. doi: 10.1016/j.trstmh.2005.06.005. Trans R Soc Trop Med Hyg. 2005. PMID: 16085172 Review.
-
Role of the private sector in the provision of immunization services in low- and middle-income countries.Health Policy Plan. 2011 Jul;26 Suppl 1:i4-12. doi: 10.1093/heapol/czr037. Health Policy Plan. 2011. PMID: 21729916 Review.
Cited by
-
Prophylactic vaccine delivery systems against epidemic infectious diseases.Adv Drug Deliv Rev. 2021 Sep;176:113867. doi: 10.1016/j.addr.2021.113867. Epub 2021 Jul 17. Adv Drug Deliv Rev. 2021. PMID: 34280513 Free PMC article. Review.
-
Potential factors influencing COVID-19 vaccine acceptance and hesitancy: A systematic review.PLoS One. 2022 Mar 23;17(3):e0265496. doi: 10.1371/journal.pone.0265496. eCollection 2022. PLoS One. 2022. PMID: 35320309 Free PMC article.
-
Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.Clin Vaccine Immunol. 2011 Jan;18(1):75-81. doi: 10.1128/CVI.00263-10. Epub 2010 Nov 3. Clin Vaccine Immunol. 2011. PMID: 21047997 Free PMC article.
-
Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection.Clin Exp Immunol. 2009 Apr;156(1):52-60. doi: 10.1111/j.1365-2249.2008.03866.x. Epub 2009 Feb 11. Clin Exp Immunol. 2009. PMID: 19220325 Free PMC article.
-
Vaccine-induced antibody isotypes are skewed by impaired CD4 T cell and invariant NKT cell effector responses in MyD88-deficient mice.J Immunol. 2009 Aug 15;183(4):2252-60. doi: 10.4049/jimmunol.0804011. Epub 2009 Jul 20. J Immunol. 2009. PMID: 19620295 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical